Literature DB >> 2509416

The postantibiotic effect of meropenem and imipenem on selected bacteria.

H L Nadler1, D H Pitkin, W Sheikh.   

Abstract

Controlled experiments were conducted to determine the in-vitro postantibiotic effect (PAE) of meropenem and imipenem on ten selected bacteria representative of medically important species: Staphylococcus aureus (2). Pseudomonas aeruginosa (4), Escherichia coli (1), Serratia marcescens (1), Morganella morganii (1), and Providencia stuartii (1). The PAE was determined by comparing serial colony counts of cultures recovering from exposure to drug concentrations at 4 x MIC for 1.5 h with the counts of drug-free controls. A PAE was observed with both meropenem and imipenem when tested against four strains of Ps. aeruginosa (meropenem PAE = 0.8-2 h; imipenem PAE = 1.2-2.5 h) and two strains of Staph. aureus (meropenem PAE = 0.7, 1.7 h; imipenem PAE = 1.7, 1.8 h). In addition, a PAE was observed with meropenem on two of four Enterobacteriaceae, E. coli ATCC 25922 (0.8 h) and Prov. stuartii (1.2 h), but not with one strain each of M. morganii and Ser. marcescens. A PAE was not observed when imipenem was tested against the four Enterobacteriaceae. Studies are suggested to investigate further the PAE of meropenem on additional strains of Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509416     DOI: 10.1093/jac/24.suppl_a.225

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.

Authors:  A Novelli; S Fallani; M I Cassetta; S Conti; T Mazzei
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 3.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.

Authors:  I Odenholt; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 6.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

7.  Pharmacodynamic effects of meropenem on gram-negative bacteria.

Authors:  H Hanberger; E Svensson; L E Nilsson; M Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

Review 8.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

Review 9.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 10.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.